Anupam Rasayan Q1 Net Profit Rises To ₹38.64 Crore Amid Basquevolt Battery Chemicals LOI

Market snapshot: Anupam Rasayan India Ltd has reported a solid performance for the first quarter ended June 30, 2026, with consolidated net profit rising 13.5% YoY to ₹38.64 crore, driven by a 34.8% YoY surge in consolidated revenue from operations to ₹654.98 crore. Additionally, the specialty chemicals player is expanding its clean mobility portfolio, highlighted by a preliminary non-binding Letter of Intent signed with Spain's Basquevolt, S.A. for a potential $300 million battery chemicals supply agreement.

Data Snapshot

• Consolidated net profit for Q1 FY27 rose to ₹38.64 crore compared to ₹34.04 crore in Q1 FY26.
• Consolidated revenue from operations increased to ₹654.98 crore in Q1 FY27 from ₹485.83 crore in Q1 FY26.
• Consolidated EBITDA grew 30.6% YoY to ₹162 crore, with EBITDA margin at 24.8% compared to 25.6% YoY.

What's Changed

• Consolidated revenue climbed by 34.8% YoY to ₹654.98 crore from ₹485.83 crore.
• Consolidated net profit grew 13.5% YoY to ₹38.64 crore from ₹34.04 crore.
• EBITDA margins slipped slightly by 80 bps to 24.8% from 25.6% in the prior year's corresponding quarter.

Key Takeaways

• Strong demand and volume recovery drove a 34.8% surge in operating revenues.
• High finance costs (up 38% to ₹49.19 crore) and depreciation (up 83% to ₹56.06 crore) absorbed much of the operating gain, reflecting the load of recent capex.
• The potential $300 million, 10-year LOI with Spain's Basquevolt highlights Anupam Rasayan's strategic inroads into specialty lithium battery chemistry.
• The Board has appointed Mr. Ravi Desai as Chief Operating Officer (COO) to drive operational improvements and handle the integration of the Bliss GVS Pharma acquisition.

SAHI Perspective

Anupam Rasayan is demonstrating robust top-line execution, showing that the global specialty chemicals industry de-stocking phase is transitioning into a recovery. However, the divergence between revenue expansion (+34.8%) and net profit expansion (+13.5%) highlights the heavy capital costs currently being carried on the balance sheet. High finance and depreciation costs from recent acquisitions (such as Jayhawk Fine Chemicals and the pending Bliss GVS Pharma deal) are eating into net margins. The appointment of a Chief Operating Officer suggests a strong emphasis on streamlining execution and driving cost synergies to translate strong sales volumes into bottom-line profits.

Market Implications

The strong top-line numbers should reassure the markets regarding custom synthesis volume momentum. The Basquevolt deal underscores long-term structural tailwinds in the EV value chain for Indian chemical manufacturers. However, near-term range-bound stock movement might persist until capital costs decline and EBITDA margins stabilize, as high debt servicing costs continue to limit immediate net margin improvements.

Trading Signals

Market Bias: Neutral

Revenue grew a stellar 34.8% YoY but net profit growth was limited to 13.5% due to an increase in capital costs. The massive $300 million Basquevolt battery chemicals LOI provides a strong long-term structural catalyst, but near-term profitability remains under pressure.

Overweight: Specialty Chemicals, EV Battery Supply Chain

Underweight: Highly Leveraged Chemical Manufacturers

Trigger Factors:

• Conversion of Basquevolt's preliminary LOI into a definitive supply contract
• Deleveraging of the balance sheet and reduction of the 38% rise in finance costs
• Successful integration and margin accrual from the Bliss GVS Pharma acquisition

Time Horizon: Medium-term (3-12 months)

Industry Context

The specialty chemicals space has faced prolonged headwinds from high-energy prices and inventory adjustments over the past two years. Aggressive custom synthesis and manufacturing (CSM) players are increasingly pivoting to high-growth areas like electronic and energy transition chemicals. Anupam Rasayan's recent breakthrough in commercializing ETFA via continuous flow technology, along with battery chemistry supply partnerships, positions it as an early mover in clean energy specialty chemicals.

Key Risks to Watch

• The Basquevolt LOI is preliminary and non-binding; conversion into actual revenues is contingent on successful product development and qualification.
• High debt load, with finance costs climbing to ₹49.19 crore, poses a risk of further bottom-line drag if integration timelines for Bliss GVS Pharma are extended.
• Revenue remains dependent on client concentration, especially with top multinational corporation customers.

Recent Developments

In July 2026, Anupam Rasayan signed a preliminary non-binding LOI with Basquevolt, S.A. for up to $300 million over 10 years. Additionally, the company is progressing its acquisition of up to 48.2% stake in Bliss GVS Pharma, with the open offer having closed in August 2026.

Closing Insight

While Anupam Rasayan's aggressive capital execution and high-profile international partnerships place it in a strong position for future electronic and EV-related chemicals demand, investors must watch for balance sheet efficiency and debt management in the coming quarters.

High Performance Trading with SAHI.